List of Excipients in Branded Drug LOPERAMIDE HCL AND SIMETHICONE

Generic Drugs Containing LOPERAMIDE HCL AND SIMETHICONE

Subscribe to access the full database, or Start Trial
Company	Ingredient	NDC	Excipient
Ohm Laboratories Inc	loperamide hcl and simethicone	51660-069	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Ohm Laboratories Inc	loperamide hcl and simethicone	51660-069	CALCIUM SILICATE
Ohm Laboratories Inc	loperamide hcl and simethicone	51660-069	CELLULOSE, MICROCRYSTALLINE
Ohm Laboratories Inc	loperamide hcl and simethicone	51660-069	SILICON DIOXIDE
Ohm Laboratories Inc	loperamide hcl and simethicone	51660-069	SODIUM STARCH GLYCOLATE TYPE A POTATO
Ohm Laboratories Inc	loperamide hcl and simethicone	51660-069	STEARIC ACID
>Company	>Ingredient	>NDC	>Excipient

What are the Most Frequently-Used Excipients in LOPERAMIDE HCL AND SIMETHICONE?

Subscribe to access the full database, or Start Trial
# Of NDCs	Excipient
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CALCIUM SILICATE
1	CELLULOSE, MICROCRYSTALLINE
1	SILICON DIOXIDE
1	SODIUM STARCH GLYCOLATE TYPE A POTATO
1	STEARIC ACID
># Of NDCs	>Excipient

Loperamide HCl and Simethicone Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Loperamide hydrochloride and simethicone is a mature over-the-counter combination for diarrhea accompanied by gas-related discomfort. The reference product, Imodium Multi-Symptom Relief, combines loperamide HCl 2 mg with simethicone 125 mg per caplet. The active ingredients are established, inexpensive and broadly available. Commercial differentiation therefore depends on excipient selection, dosage-form performance, packaging, consumer positioning, channel economics and regulatory execution rather than new-molecule exclusivity.

The strongest opportunities are chewable and orally disintegrating formats, improved swallowability, lower-sugar products, private-label supply, travel packs, pediatric-adjacent but appropriately labeled products, and packaging designed to reduce misuse and dosing errors. Patent barriers are limited. The main competitive barriers are brand recognition, FDA compliance, manufacturing scale, retailer access and formulation consistency.

What is the FDA regulatory status of loperamide HCl and simethicone?

Loperamide HCl and simethicone is generally marketed in the United States as an OTC combination under FDA nonprescription-drug requirements.

Component	Function	Typical strength in the combination	FDA regulatory position
Loperamide hydrochloride	Antidiarrheal; reduces intestinal motility and secretion	2 mg	OTC antidiarrheal active ingredient
Simethicone	Antiflatulent; reduces surface tension of gas bubbles	125 mg	OTC antiflatulent active ingredient
Combination	Treats diarrhea with gas-related symptoms	2 mg/125 mg per unit	Marketed under OTC labeling and applicable monograph requirements

FDA regulations identify loperamide as an OTC antidiarrheal active ingredient and simethicone as an OTC antiflatulent active ingredient. The combination product must comply with the applicable Drug Facts labeling, dosage limits, warnings, directions and manufacturing requirements under the Federal Food, Drug, and Cosmetic Act and current good manufacturing practice rules. [1-4]

The product is not a biologic and does not face biosimilar competition. It is also not a conventional small-molecule prescription product whose commercial protection depends on an active Orange Book patent estate.

What formulations are protected by loperamide HCl and simethicone patents?

The commercial formulation has limited patent protection compared with newer prescription medicines. Loperamide and simethicone are long-established active ingredients, and basic composition-of-matter protection has expired.

The relevant intellectual-property assets are more likely to involve:

Specific loperamide-simethicone dosage forms
Taste masking
Chewable or orally disintegrating tablets
Effervescent or rapid-dispersion systems
Controlled-release delivery
Bilayer tablets separating incompatible ingredients
Manufacturing processes
Packaging and unit-dose systems
Abuse-deterrent designs
Combination claims covering diarrhea and gas symptoms

These rights would need to satisfy novelty and non-obviousness requirements over a large body of prior art. A patent claiming only the combination of 2 mg loperamide HCl and 125 mg simethicone would face a substantial obviousness challenge if comparable combination products and disclosures were already public.

Is the combination listed in the Orange Book?

The branded OTC combination is not primarily protected through an active Orange Book patent listing. The Orange Book is principally used for approved prescription and certain approved nonprescription drug applications. OTC monograph products generally do not obtain the same patent-listing and Paragraph IV framework that applies to abbreviated new drug applications referencing an approved NDA.

A company developing a competing OTC product should assess:

Whether the product is monograph-compliant.
Whether an approved NDA or ANDA pathway is required.
Whether any branded product has an active approved application with listed patents.
Whether formulation, process or packaging patents exist outside the Orange Book.
Whether the proposed labeling copies protected trade dress or creates trademark risk.

Patent clearance must include USPTO records, FDA application records, published applications, assignment databases and litigation databases. A freedom-to-operate review limited to the Orange Book would be incomplete.

When does loperamide HCl and simethicone lose exclusivity?

The active ingredients have already lost basic exclusivity. There is no meaningful new-molecule exclusivity remaining for either component.

Exclusivity category	Position
Loperamide composition of matter	Expired
Simethicone composition of matter	Expired
Basic combination concept	Mature and commercially established
OTC monograph access	Available to compliant manufacturers
Brand protection	Ongoing through trademarks, trade dress and distribution
Formulation patents	Potentially relevant, but narrow and claim-specific
Regulatory exclusivity	Not a principal barrier for a standard monograph product
Biosimilar exclusivity	Not applicable

A rival can generally compete through a compliant OTC product without waiting for a reference product’s new-drug exclusivity period to expire. The commercial launch risk is therefore concentrated in formulation equivalence, labeling, quality control, retailer acceptance and intellectual-property clearance.

What excipient strategy is appropriate for the combination?

The excipient strategy should account for two active ingredients with different physical and functional requirements. Loperamide HCl is used at a low dose, while simethicone is used at a much higher mass and may be supplied as a dispersion or emulsion rather than a conventional freely soluble powder.

Immediate-release caplet strategy

A conventional immediate-release caplet is the lowest-risk platform. The formulation should prioritize:

Uniform distribution of the 2 mg loperamide dose
Consistent simethicone dispersion
Rapid disintegration
Low tablet friability
Acceptable swallowing characteristics
Stable performance under heat and humidity
Minimal interaction between simethicone and aqueous excipients

Common excipient categories include:

Excipient category	Technical purpose
Microcrystalline cellulose	Diluent and compression aid
Dibasic calcium phosphate or similar mineral diluent	Tablet mass and hardness
Croscarmellose sodium or crospovidone	Disintegration
Colloidal silicon dioxide	Glidant and moisture management
Magnesium stearate	Lubrication
Povidone or related binder	Granulation and tablet strength
Film-coating polymers	Appearance, swallowability and moisture protection
Talc	Processing and coating aid
Colorants	Product identification and brand differentiation

The formulation should avoid unnecessary complexity. In a mature OTC product, every added excipient can increase supply-chain exposure, allergen or intolerance questions, analytical burden and reformulation risk.

Chewable tablet strategy

A chewable format has the clearest commercial rationale because the product is used during acute gastrointestinal symptoms and may be taken while traveling or away from water.

The key excipient requirements are:

Effective taste masking for loperamide HCl
Low grittiness from simethicone and mineral excipients
Adequate mechanical strength
Controlled mouthfeel
Limited aftertaste
Moisture-resistant packaging
Rapid dose availability after chewing

Potential excipient tools include mannitol, sorbitol, xylitol, compressible sugars, polymeric taste-masking agents and high-intensity sweeteners. Polyols can improve taste and cooling sensation, but excessive quantities can worsen gastrointestinal discomfort. That creates a direct formulation constraint: the product is intended for gastrointestinal symptoms, so the sweetener system should not introduce a meaningful laxative burden.

A sugar-free, low-polyol system may command a premium if it preserves taste and avoids consumer concern about sugar content. The product should not rely on a large sorbitol load to solve loperamide bitterness.

Orally disintegrating tablet strategy

An orally disintegrating tablet could target consumers who have difficulty swallowing caplets. The commercial value would depend on achieving true rapid dispersion without producing a sandy or oily mouthfeel from simethicone.

Important development variables include:

Particle-size control for simethicone
Taste-masking efficiency
Tablet porosity
Mechanical resistance during packaging and transport
Moisture protection
Dose uniformity at low loperamide loading
Disintegration time under compendial and in-use conditions

Aluminum-aluminum blister packaging or high-barrier unit-dose packaging may be required if the tablet is moisture-sensitive. Packaging cost can materially affect margins in a low-price OTC category.

Liquid or suspension strategy

A liquid product would expand access for consumers who cannot swallow tablets, but it creates greater formulation and quality risks. Simethicone is poorly water-soluble and typically requires suspension or emulsion technology. Loperamide HCl must remain uniformly distributed at a low concentration.

A liquid product would require close control of:

Sedimentation and redispersibility
Preservative effectiveness
Container compatibility
Dose-measuring accuracy
Flavor stability
Microbial limits
Shake-well instructions
In-use shelf life

A liquid may have a place in international or institutional channels, but it is less attractive than a solid oral format for a U.S. mass-market launch because of logistics, dosing complexity and stability requirements.

What excipients create the strongest commercial differentiation?

The most valuable excipient decisions are those that improve a measurable consumer attribute.

Consumer need	Formulation response	Commercial value
Difficulty swallowing	Chewable or orally disintegrating tablet	Broadens use occasions
Bad taste	Taste masking, flavor system and sweetener optimization	Supports premium positioning
Sugar avoidance	Sugar-free formulation with limited polyols	Supports wellness and diabetic-friendly positioning, subject to compliant claims
Travel convenience	Compact blister or single-dose sachet	Enables airport, hotel and convenience channels
Fast use	Rapid-disintegration tablet	Supports acute-symptom positioning
Low pill burden	Higher simethicone strength per unit	Differentiates from loperamide-only products
Packaging concerns	Unit-dose, child-resistant and tamper-evident packaging	Reduces dosing and misuse risk
Ingredient sensitivity	Exclusion of selected dyes, lactose or gluten-containing excipients where supportable	Enables targeted private-label variants

The formulation should not imply faster clinical action unless the product has supporting evidence. Rapid disintegration does not automatically establish faster therapeutic relief.

How strong is the patent estate for loperamide HCl and simethicone?

The patent estate is weak at the active-ingredient level and potentially moderate for narrowly drafted delivery or manufacturing claims.

Patent-strength assessment

Asset type	Relative strength	Business impact
Loperamide composition claims	Low	Expired
Simethicone composition claims	Low	Mature ingredient
Basic fixed-dose combination	Low to moderate	Vulnerable to prior-art challenges
Taste-masked chewable formulation	Moderate if technically specific	May delay direct copying
ODT or rapid-dispersion system	Moderate	Depends on claim construction and prior art
Manufacturing process	Moderate	Can create practical barriers if difficult to reproduce
Packaging and trade dress	Moderate	More relevant to brand enforcement than market exclusivity
Therapeutic method claims	Low to moderate	OTC labeling and prior art reduce scope
Proprietary supplier technology	Moderate	Could affect cost and scale even without patents

A competitor should not assume that the absence of an Orange Book patent means the product is free of all IP risk. Process patents, formulation patents, trademarks, design rights and trade dress can remain relevant.

What Paragraph IV challenges and generic entry risks exist?

A standard OTC competitor is unlikely to use Paragraph IV litigation as its primary entry mechanism. Paragraph IV certifications are associated with ANDAs referencing listed patents for approved drug applications. A monograph-compliant OTC product generally reaches the market through a different regulatory route.

The key entry scenarios are:

A direct monograph-compliant tablet launch.
A private-label product manufactured for a retailer.
An authorized store-brand product using an established contract manufacturer.
A new dosage form supported by an NDA or other applicable FDA pathway.
A product that changes the indication, strength, route or labeling and therefore triggers a different regulatory analysis.

The main legal exposure is likely to involve trademark infringement, trade dress, false or misleading labeling, patent claims directed to a specific formulation, and consumer-protection allegations. A generic manufacturer should avoid copying the reference product’s color pattern, tablet appearance, carton layout or distinctive claims unless cleared.

Which companies are challenging the branded market?

The market is challenged primarily by retailer private labels and established OTC manufacturers rather than by biotechnology companies or specialty generic firms.

Competitive participants can include:

Brand owners selling loperamide-only products
Retailer private-label manufacturers
Contract manufacturers supplying national pharmacy chains
International OTC companies
E-commerce sellers offering multipacks and travel formats
Combination-product developers using alternative gas-relief actives

The most direct competitive products are loperamide-only products and loperamide-simethicone combinations. Loperamide-only products compete on price and broad diarrhea relief. Combination products compete on convenience for consumers who associate diarrhea with bloating, pressure or gas.

How does loperamide HCl and simethicone compare with loperamide-only products?

Attribute	Loperamide HCl and simethicone	Loperamide-only
Primary use	Diarrhea with gas-related discomfort	Diarrhea
Consumer proposition	Two-symptom treatment in one product	Lower-cost single-purpose treatment
Formulation complexity	Higher	Lower
Tablet mass	Higher because of simethicone	Lower
Manufacturing risk	Greater dispersion and uniformity challenges	Simpler compression platform
Retail pricing	Potential premium	Strong price competition
Patent exposure	Combination and formulation claims	Mostly mature ingredient and brand issues
Best commercial channel	Travel, convenience, pharmacy and family OTC	Broad mass retail and value channels

The combination can justify a premium if consumers perceive a meaningful benefit from treating gas symptoms with the same dose. The label must remain within permitted OTC indications and must not imply treatment of serious abdominal conditions.

What licensing deals and manufacturing barriers matter?

Public licensing economics for the specific loperamide HCl and simethicone combination are limited because the product is mature and widely manufacturable. Commercial deals are more likely to involve:

Private-label supply agreements
Contract manufacturing
Regional distribution rights
Brand licensing
Packaging and formulation technology licenses
Flavor and taste-masking technology
High-barrier blister systems
Retailer-exclusive products

Manufacturing barriers are practical rather than fundamental. They include low-dose loperamide content uniformity, simethicone dispersion, coating consistency, tablet robustness, microbial control and packaging shelf life.

A supplier with validated content-uniformity and simethicone-dispersion processes can compete effectively even without strong patent protection. Conversely, a technically simple formulation can fail commercially if it produces inconsistent tablets, poor taste or unacceptable sedimentation.

What commercial opportunities exist?

The most attractive opportunities are incremental products that solve a specific use problem.

Premium consumer products

A premium chewable or orally disintegrating product could target travel, camping, festivals and workplace use. The product should emphasize portability, taste and no-water administration rather than unsupported claims of faster efficacy.

Private-label expansion

Retailers can use the combination to fill a gap between low-cost loperamide-only products and branded combination products. A manufacturer with a flexible packaging line can offer:

Store-brand caplets
Unit-dose blister packs
Sugar-free chewables
Small travel cartons
Club-store multipacks
E-commerce bundles

Private-label economics depend on low component cost, high line throughput and stable access to loperamide HCl and simethicone suppliers.

International markets

Outside the United States, dosage strengths, indications, naming conventions and regulatory pathways vary. Opportunities exist in markets where consumers prefer antidiarrheal and antiflatulent combinations, but local restrictions on loperamide labeling, pack size and pharmacy status must be assessed separately.

Geographic expansion should begin with markets that accept established OTC combination products and have predictable requirements for stability, bilingual labeling, pharmacovigilance and import registration.

Hospital and institutional channels

Institutional buyers may value unit-dose packaging, barcode compatibility, tamper evidence and predictable dosing. The price opportunity is lower than in premium consumer retail, but recurring procurement can support volume.

What revenue exposure does the product create?

Product-specific revenue for Imodium Multi-Symptom Relief is not generally disclosed as a separate public line item. The commercial exposure is best assessed through category-level factors:

U.S. OTC diarrhea-treatment volume
Branded versus private-label share
Retail distribution
Seasonal demand
Travel and convenience use
Average selling price
Pack-size architecture
Promotional intensity
Gross margin after retailer deductions

The combination can produce higher revenue per unit than loperamide-only products, but it also has higher manufacturing and packaging costs. The likely margin advantage depends on whether the product achieves a price premium that exceeds the incremental cost of simethicone, taste masking, higher tablet mass and specialized packaging.

What litigation and settlement issues affect the product?

There is no central, well-known current patent litigation campaign defining the loperamide HCl and simethicone market. Litigation risk is more likely to arise from:

Product liability and misuse claims involving loperamide
Labeling and warning adequacy
Trademark and trade dress disputes
False advertising
Patent claims against a novel dosage form
Manufacturing-quality disputes
Retailer or distributor contract claims

Loperamide products also face heightened scrutiny because excessive doses can produce serious cardiac and neurologic risks. Packaging, label warnings, unit-dose limits and anti-abuse positioning should be treated as commercial and legal design inputs, not only regulatory details. FDA has warned about serious heart problems associated with high doses of loperamide, including doses exceeding the labeled amount. [5]

Key Takeaways

Loperamide HCl and simethicone is a mature OTC combination with limited active-ingredient patent protection.
The principal U.S. reference product is Imodium Multi-Symptom Relief, typically containing 2 mg loperamide HCl and 125 mg simethicone per caplet.
The product is generally governed by OTC monograph and Drug Facts requirements rather than a conventional Paragraph IV-centered exclusivity model.
The strongest formulation opportunities are chewable, orally disintegrating, sugar-free and travel-friendly products.
Excipients should solve taste, mouthfeel, disintegration, content uniformity and moisture-protection problems.
Excessive polyol use is commercially unattractive because gastrointestinal products should not introduce avoidable laxative effects.
Patent value is most likely to reside in narrow formulation, process, packaging or delivery claims.
Brand, trade dress, retailer access, manufacturing validation and compliant labeling are more important barriers than composition-of-matter patents.
No biosimilar risk exists because the product is not a biologic.
Private-label and contract-manufacturing opportunities are substantial because the active ingredients are mature and supply chains are established.

FAQs

Can loperamide HCl and simethicone be developed as a sugar-free chewable?

Yes. A sugar-free chewable is technically feasible, but the sweetener system must control loperamide bitterness without relying on excessive sorbitol, mannitol or other polyols that may worsen gastrointestinal symptoms.

Is simethicone compatible with immediate-release loperamide tablets?

Yes, but compatibility depends on particle distribution, excipient selection, granulation conditions and moisture exposure. Simethicone’s physical dispersion properties are more important than chemical reactivity alone.

Does an orally disintegrating version receive separate FDA exclusivity?

Not automatically. A new dosage form may support patent claims or a distinct FDA application, but exclusivity depends on the regulatory pathway and the specific approved product.

Can a company launch a private-label version without licensing the Imodium brand?

Yes. A compliant private-label product can be developed without a brand license, provided it uses lawful labeling, avoids protected trade dress and clears applicable patents, trademarks and regulatory requirements.

Is a loperamide-simethicone combination appropriate for pediatric commercialization?

Pediatric positioning requires strict compliance with FDA labeling, age restrictions, dosing instructions and safety warnings. A product should not assume that adult combination labeling can be extended to children without a specific regulatory and clinical assessment.

References

U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 333: External analgesic and antidiarrheal drug products for over-the-counter human use. https://www.ecfr.gov/
U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 332: Antiflatulent drug products for over-the-counter human use. https://www.ecfr.gov/
U.S. Food and Drug Administration. (2024). Over-the-counter drug review and monograph information. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
DailyMed. (2024). Imodium Multi-Symptom Relief loperamide hydrochloride and simethicone tablet, film coated: Product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (2018). FDA warns about serious heart problems with high doses of the diarrhea medicine loperamide, including abuse and misuse. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Patent and Trademark Office. (2024). Patent Center and patent public search. https://www.uspto.gov/ patent search.

More… ↓

⤷ Start Trial